Introduction
Restenosis after coronary angioplasty remains a significant clinical problem with > 30% restenosis rates at 6 mo (1). The restenosis is caused predominantly by an accumulation of vascular smooth muscle cells (VSMC) ( 1 ),1 extracellular matrix, 1 . Abbreviations used in this paper: GAPDH, glyceraldehyde phosphate dehydrogenase; a-sm-actin, a-smooth muscle actin; VSMC, vascular smooth muscle cells. and collagen (2) . Many pharmacological inhibitors of VSMC proliferation have been identified in vitro, and some, including heparin, angiotensin-converting enzyme inhibitors, and interferon-y, have also been found to inhibit the neointima that leads to restenosis in vivo, in animal models ofarterial restenosis (3) (4) (5) (6) (7) (8) . However, no agent has yet been found that successfully inhibits angioplasty restenosis in human trials (see reference 9 for review). Recent research has therefore examined the potential of using antisense oligodeoxynucleotides to identify genes whose expression is important in VSMC proliferation as a step toward novel therapy. Antisense oligodeoxynucleotides are short synthetic DNA molecules whose sequences are complementary to those present in specific target mRNAs within cells. Antisense oligonucleotides complementary to sequences in the proto-oncogene c-myb and the genes for nonmuscle myosin and proliferating cell nuclear antigen have all been found to reduce arterial proliferation in vitro (10) (11) (12) . In addition, antisense c-myb oligonucleotides can also reduce neointimal formation in vivo ( 13) .
The c-myc oncogene is homologous to the transforming gene of the avian myelocytoblastosis virus MC29 and has long been implicated in the control of normal and abnormal cell proliferation ( 14) . C-myc encodes a short-lived sequence-specific DNA-binding nuclear phosphoprotein thought to be involved in transcriptional modulation. Mitogen stimulation of quiescent VSMCs rapidly induces c-myc with a peak ofexpression at 2-4 h ( 15, 16). Subsequently, c-myc expression in VSMCs is maintained at a constant low level throughout the first and subsequent cell cycles ( 17) . C-myc thus appears to have a role both in entry into the cell cycle and in the maintenance of cell proliferation. Consistent with this, we have recently shown that c-myc down-regulation is an essential component of the antiproliferative action of a variety of VSMC growth inhibitors ( 18) . The constant requirement for low level expression of c-myc in proliferating VSMCs and the short halflife ofc-myc mRNA and protein all conspire to make c-myc an attractive target for antisense inhibition. Indeed, antisense cmyc oligonucleotides have previously been shown to reduce proliferation and/or increase differentiation in a number of cell lines (19) (20) (21) (22) (23) (24) .
Recently antisense c-myc oligonucleotides have been demonstrated to exert antiproliferative effects on animal and human VSMCs in vitro (25, 26) but no study has examined the effects of antisense c-myc oligonucleotides on VSMCs in vivo. We have therefore used an antisense c-myc oligodeoxynucleotide analogue, previously demonstrated to be stable in culture, to enter cells and form hybrid duplexes, and to reduce c-Myc protein levels (20) , and examined its effects on the proliferation of VSMCs both in vitro and in vivo using a rat carotid artery injury model of restenosis. We have also examined the effects of antisense sequences complementary to sequences in muscle actin [ a-sm-actin ] and glyceraldehyde phosphate dehydrogenase [GAPDH]).
Methods
Cell culture. VSMCs were isolated from thoracic aortic explants of 6-wk-old Sprague-Dawley rats. Cells were cultured in DME containing 10% FCS (Gibco, Grand Island, NY) 20 mM Hepes (Flow Laboratories, Melcan, VA) and equilibrated with 95% air and 5% CO2. Subconfluent cells were passaged by trypsinization in 0.05% trypsin in PBS and reseeded in DME + 10% FCS (normal culture medium). VSMCs were identified by their typical "hill and valley" morphology in culture and by immunocytochemical staining for a-sm-actin (Sigma Chemical Co.
[St. Louis, MO] monoclonal anti-sm-muscle a-actin antibody). Cells at passage 5 were used for experiments and retroviral infections.
Production of VSM-myc cell lines. The retroviral vectors used to generate VSMC lines that constitutively express elevated c-Myc protein levels (VSM-myc cells) were constructed by inserting a full-length human c-myc cDNA into the pDORneo retroviral vector (27) . This vector contains the Moloney murine leukemia virus long terminal repeat which drives expression of the c-myc sequence and an internal Simian virus 40 (SV40) promoter from which the neomycin resistance gene is expressed. Normal rat VSMCs were plated in 90-mm tissue culture plates at a density of 2 X I07 cells per plate and left in normal culture medium for 24 h. The medium was then aspirated and replaced with 2 ml of medium containing virus (the supernatant of a 90-mm plate of GP + E packaging cells harvested at 48 h after infection) diluted at 1:50 in media and 8 Ag/ml of polybrene at 37°C for 2 h. This medium was then aspirated and replaced with 10 ml of normal medium for 24 h. The cells were then trypsinized, split 1:20, and cultured in normal medium for 24 h. The following day, 500 Ag/ml of G418 (Genticin; Gibco) was added to the growth medium and resistant clones were selected. Individual clones were picked, plated into individual flasks, and cultured in medium containing 500 ttg/ml of G418. A clone of VSM-myc cells was used which constitutively expressed 7 x normal c-Myc protein levels as assessed by c-Myc protein ELISA (28) . Absolute levels of intracellular c-Myc protein expression were determined using a bacterially expressed c-Myc protein as standard (28) and see below.
Synthesis and purification of oligodeoxynucleotide. Phosphorothioate-derivatised oligodeoxynucleotides were synthesized on an automated synthesizer (model 380B, Applied Biosystems Inc., Foster City, CA). After deprotection, oligodeoxynucleotides were dissolved in water, extracted with phenol/chloroform/isoamyl alcohol (49.5:49.5:1), precipitated with ethanol, and redissolved in water. Concentrations were determined spectrophotometrically by assuming 1 A260 unit = 33 Ag RNA. All oligodeoxynucleotides used were 15-mers. The c-myc sense oligodeoxynucleotide sequence comprised the first 5 codons of human c-myc mRNA (5' ATGCCCCTCAACGTT 3') and antisense c-myc oligodeoxynucleotides comprised the complementary sequence AACGTTGAGGGGCAT. Other oligodeoxynucleotides used were (a) a 2-bp internal mismatch antisense c-myc sequence (2-bp internal mismatch) (5' AACGTGGAG7IGCAT 3'); (b) a sequence complementary to the first 5 codons of rat (GAPDH) mRNA (5' ACCGACCTT-CACCAT 3'); and (c) a sequence complementary to part of the 5' noncoding sequence of rat VSMC a-sm-actin mRNA (5' ATGGCG-ACTGGCTGG 3'). The a-sm-actin sequence was chosen on the basis of minimal complementarity to sequences in either fi-or y-actin gene isoforms.
Cell proliferation studies. To determine VSMC proliferation, VSMCs were plated into 24-well plates at 1 x 104 cells/well and cultured in DME + 0.5% FCS for 72 h (day 0). The medium was then replaced with DME + 10% FCS alone or with 5-30 Ag/ml of antisense c-myc oligodeoxynucleotides or 30 Ag/ml of one of the other oligodeoxynucleotide sequences. Triplicate wells were trypsinized to release cells and the cells counted by trypan blue exclusion on a hemocytometer at appropriate time points. To study proliferation of logarithmic phase cells, VSMCs were plated into 24-well plates at 1 X 104 cells/well and cultured in DME + 10% FCS for 48 h (day 0). 5-30 ,ug/ml of antisense c-myc or 30 ,g/ml of one of the other oligodeoxynucleotide sequences were then added to the media of triplicate wells and cell number counted as above at appropriate time points.
Rat carotid artery model of intimal hyperplasia. Intimal hyperplasia was induced by balloon catheter dilatation of the carotid artery of the rat. Male rats (300-350 g) were anesthetized by intraperitoneal injection of fentanyl (Janssen Pharmaceutica) and midazolam (Roche) and the neck was incised. Left common carotid injury was induced by the passage of a Fogarty balloon embolectomy catheter (FG2) (Baxter Healthcare Corp., Deerfield, IL), inserted via the left external carotid artery and distended with 20 ,1 of saline as described by Clowes et al. (29) . In experiments designed to examine the time course of c-myc induction after injury, the left common carotid artery was injured, the neck wound was repaired, but the rats were kept under anesthesia until they were killed by exsanguination 1-4 h later. Injured left and uninjured right common carotid arteries were removed and snap-frozen in liquid nitrogen for RNA extraction. In studies examining the effect of antisense oligodeoxynucleotides on c-myc mRNA expression, antisense c-myc (n = 6) or sense c-myc (n = 6) oligodeoxynucleotides were applied to the adventitial surface of the arterial wall in a pluronic gel solution. Sense and antisense c-myc oligodeoxynucleotides were dissolved in a 0.25% pluronic gel solution at 40C (F127, BASF Corp.) at I mg/ml. 200 ,1 of the gel solution was applied to the distal third of the common carotid artery, immediately after vessel injury, as described by Simons et al. ( 13 ) . The animals were kept under anesthesia and the artery removed 2 h later for RNA extraction. In studies examining the neointimal response to injury, 200 gg of antisense c-myc (n = 9) or sense c-myc (n = 5) oligodeoxynucleotides were applied as above immediately after injury. Pluronic gel alone was applied to further injured vessels (n = 5). The neck wounds were then repaired and the animals allowed to recover. 14 d after injury, the rats were reanesthetised and killed by exsanguination through an aortic cannula, and the carotid artery was fixed in situ by perfusion with 1% paraformaldehyde and 2% glutaraldehyde at 120 mmHg perfusion pressure for 10 min. The left and right common carotid arteries were excised and placed in the same fixative for a further 16 h before processing and embedding in Araldite epoxy resin. 2-tim sections were stained with toluidine blue and the cross-sectional area of neointima measured for the proximal (untreated) and distal (treated) thirds of the artery. A cross section of the artery was examined microscopically and viewed using a X4 objective. The image was digitized by a ContextVision Gop-302 image analysis computer using the green channel of a JVC-M280 TV camera mounted on the microscope. The image area corresponded to 2.1 mm2 of the section. Using a mouse-controlled cursor, the boundaries of the intima and media were traced onto the image display. The area ofeach traced region and the mean distance between neighboring boundaries were calculated.
RNA isolation and Northern hybridization. Total RNA from cultured cells was isolated by the method of Chirgwin et al. (30) . 107 normal rat VSMCs were grown in DME + 10% FCS until 50% confluent. 30 ,g/ml of sense c-myc, antisense c-myc, 2-bp mismatch antisense c-myc, antisense a-sm-actin, or antisense GAPDH oligodeoxynucleotides were then added to the medium and RNA isolated from cells after 24 h. PolyA+ RNA was isolated from whole rat carotid arteries using the Micro-Fast Track System (Invitrogen). RNA was quantified spectrophotometrically. 15 ,ug of total RNA or 0.5 jig of polyA+ RNA per time point was electrophoretically fractionated on a 1% agarose gel containing 2.2 M formaldehyde in a lx Mops running buffer (200 mM 3-(N-morpholino) propanesulphonic acid, 8 mM sodium acetate, 1 mM EDTA), blotted onto Hybond-N (AAmersham International, Amersham, Bucks, UK) nylon filters using 20x SSC as a transfer buffer overnight ( lx SSC is 0.3 M NaCl and 0.3 M trisodium citrate), and the RNA was bound and cross-linked using UV radiation (StratalinkerStratagene Ltd.). C-myc mRNA was detected using a riboprobe from a linearized human c-myc fragment D4 14-433( 31 ) and signals were normalized against a random primed (Amersham Int.) rat GAPDH cDNA probe. Filters were prehybridized in 6x SSC, 5 X Denhardt's solution, 5 ,g/ml denatured salmon sperm DNA (Sigma), 0.2% SDS, and 50% formamide. Prehybridization was performed at 650C (c-myc riboprobe) or 420C (GAPDH probe) for 1 h and hybridization for 16 h at the above temperatures. The filters were then washed with 6x SSC, 0.1% SDS and 2x SSC, 0.1% SDS at 580C, and exposed using a Cronex intensifying screen (DuPont Co.) and Kodak-X-omatic AR film at -700C overnight. For repeat hybridizations, the filters were stripped by boiling in 0.1% SDS for 1 h and exposing overnight to verify loss of signal. Scanning densitometry was used to determine changes in mRNA levels.
Immunocytochemical analysis of c-Myc protein. VSMCs were plated onto eight-well Tissue-Tek chamber slides (LabTek Ltd.) and cultured for 48 h in DME containing 10% FCS. The medium was then replaced with DME + 10% FCS alone or with 30 ,g/ml ofsense c-myc, antisense c-myc, 2-bp mismatch antisense c-myc, antisense a-sm-actin, or antisense GAPDH oligodeoxynucleotides. Cells were fixed and processed after 24 h using an affinity-purified pan-myc antibody as described before (32 ----0a---Control 5ug/ml 1 Oug/ml 15ug/ml 20ug/ml 25ug/ml 3 in significant reduction in increase in live cell number from day 2 onwards (P < 0.05 versus control cells) and the extent of inhibition was proportional to the concentration of antisense oligodeoxynucleotides present (Fig. 1) . No significant inhibition of proliferation was observed in cells incubated with sense c-myc, a 2-bp internal mismatch antisense c-myc, antisense a-sm-actin, or antisense GAPDH oligodeoxynucleotides. Significant reduction ofproliferation (P < 0.05) from day 2 onwards was also observed in exponentially proliferating VSMCs after antisense c-myc oligodeoxynucleotide treatment (Fig. 2) . Inhibition of proliferation was also proportional to concentration of the antisense c-myc oligodeoxynucleotide (Fig. 2) . 50% inhibition of proliferation (IC50) occurs at an oligodeoxynucleotide concentration of 10 (Fig. 3) and protein (Fig. 4) . Scanning densitometry showed that average c-myc mRNA level was reduced by -50% after 24 h incubation with antisense c-myc oligodeoxynucleotides. C-Myc protein levels in cells were examined by quantitative immunofluorescence and showed a 55% (±5%) reduction after 24 h incubation in antisense c-myc oligodeoxynucleotides. The reduction in c-Myc immunofluorescence occurs in each cell, with a < 10% variability between cells (Fig. 4) . The observed reduction in VSMC c-Myc protein levels was confirmed in bulk populations of cells by ELISA (Table I) . In contrast to the effects ofthe antisense c-myc oligodeoxynucleotides, we observed no significant reduction in cmyc mRNA levels after incubation with sense c-myc, the 2-bp internal mismatch antisense c-myc, a-sm-actin or antisense GAPDH control oligodeoxynucleotides (Fig. 3) . Levels of c- Myc protein in VSMCs were similarly unaffected by these control oligodeoxynucleotides, as determined by immunofluorescence (Fig. 4) and ELISA (Table I) . VSM-myc cells, expressing high levels of c-Myc protein, showed no change in c-Myc protein levels after treatment with antisense c-myc oligodeoxynucleotides (Fig. 4 B and Table I ).
Expression of c-myc in arteries after balloon injury. We examined the induction of c-myc in rat carotid arteries after injury with a balloon catheter. RNA was extracted from injured and uninjured arteries at various times, fractionated on agarose gels, and probed for c-myc expression. After balloon arterial injury ofthe left carotid artery we observed a characteristic temporal sequence of c-myc mRNA induction. Little detectable c-myc mRNA was evident at time 0. Injury caused the rapid induction of c-myc mRNA which peaks after 2 h and which was still detectable, albeit at a lower level, after 4 h (Fig.  5) . No such induction of c-myc was detected in the uninjured right carotid arteries. The application of antisense c-myc oligodeoxynucleotides to the adventitial surface of the arterial wall reduces the 2-h c-myc mRNA peak by -75% (Fig. 5) . No such reduction in c-myc mRNA was observed after application of sense c-myc oligodeoxynucleotides (Fig. 5) .
Effect ofantisense c-myc oligodeoxynucleotides on arterial neointima formation. We next examined the effect on arterial neointimal formation of application of antisense c-myc oligodeoxynucleotides to the adventitial surface of the arterial wall immediately after balloon catheter injury. Neointimal areas were assessed in the distal treated segments and proximal untreated segments of the arteries 14 d after injury (Fig. 6 and 7) . Application of antisense c-myc oligodeoxynucleotide significantly reduced neointimal formation following balloon injury (P < 0.05) when compared with either sense c-myc oligodeoxynucleotide or application of gel alone (Fig. 6 and 7) . The reduction in neointimal area was localized to the areas to which the gel containing antisense c-myc oligodeoxynucleotides had been applied: proximal sections of the artery showed similar neointimal areas in all groups (Figs. 6 and 7) . Some degree of variability was observed in the amount of neointima present in the antisense c-myc-treated group. Four out of nine arteries exhibited virtually no neointima formation in the antisense c-myc-treated segments, despite a markedly thickened intima in the proximal, untreated segment of the same vessel (Figs. 6  B and 7) .
Discussion
Antisense oligodeoxynucleotides complementary to sequences in specific genes are useful probes for examining the requirement for expression those genes in various biological processes. Antisense strategies have been successfully used to investigate single gene function in VSMC proliferation (10-13, 25, 26) . We demonstrate here that antisense oligodeoxynucleotides complementary to sequences in the c-myc proto-oncogene suppress in vitro, in a dose-dependent fashion, the proliferation of VSMCs stimulated by mitogens from quiescence and also exponential proliferation of VSMCs already in the cell cycle. At an antisense oligodeoxynucleotide concentration of 30 ,g/ml, inhibition of proliferation is almost complete. The inhibitory effect of antisense c-myc oligodeoxynucleotides on proliferation of serum-stimulated quiescent VSMCs and exponentially proliferating VSMCs implies that c-myc expression is required both for VSMCs to enter the cell cycle and also for continuous proliferation.
Concentrations of c-myc antisense oligodeoxynucleotides that significantly inhibit cell proliferation suppress c-myc mRNA and protein to -45-50% ofthe normal levels in proliferating cells. Although incomplete, this suppression of c-myc expression appears sufficient to inhibit VSMC proliferation and is consistent with a previous analogous study in HL60 promyelocytic leukaemia cells (20) . In contrast to an earlier study on VSMCs (26) we have observed no significant growth stimulatory effect from low-dose antisense c-mycoligodeoxynucleotides. The inhibition of proliferation we observe appears to be a sequence-specific effect of antisense c-myc oligodeoxynucleotides because no growth inhibition or suppression of expression of c-myc mRNA and c-Myc protein was observed after incubation of VSMCs with a sense c-myc oligodeoxynucleotide, a 2-bp mismatch antisense c-myc oligodeoxynucleotide, or oligodeoxynucleotides complementary to sequences in genes for a-sm-actin or GAPDH. It is interesting to note that antisense GAPDH oligodeoxynucleotides had no observable effect on GAPDH message levels; nor indeed did antisense asm-actin affect corresponding a-sm-actin mRNA levels (data not shown). We suggest that this is due to the relatively high RCA LCA LCA (34) . Any effects ofantisense deoxynucleotides might therefore be due to degradation of nontargeted mRNAs. To try to eliminate this possibility, and to confirm the specificity of action of the c-myc antisense oligodeoxynucleotide in our system, we asked whether the inhibition ofcell proliferation mediated by antisense c-myc oligodeoxynucleotides is overcome by elevated expression of exogenous c-myc. We found that VSMCs that overexpress c-myc from an exogenous retrovirus promoter (VSM-myc cells) are not growth inhibited by concentrations of antisense c-myc oligodeoxynucleotides that induce almost complete growth arrest in normal VSMCs, nor are their intracellular levels of c-Myc protein significantly suppressed. This is consistent with the notion that elevated c-myc mRNA can titrate out the growth-inhibitory effect of antisense c-myc oligodeoxynucleotide and suggests that antisense c-myc oligodeoxynucleotides block VSMC proliferation by sequence-specific interaction with c-myc mRNA. Nonetheless, it remains possible that antisense oligodeoxynucleotides work by some alternative mechanism that does not involve sequestration and degradation of c-myc mRNA, for example by direct interaction with some intracellular protein. Presumably, such an interaction would also be competitively titrated by overexpression of c-myc.
Following balloon catheter injury, c-myc expression is rapidly induced in the arterial wall, with the peak ofexpression at 2 h (as shown here and in references 35 and 36) . This peak expression is significantly suppressed by the application of antisense c-myc oligodeoxynucleotides to the adventitial surface ofthe arterial wall, arguing that the oligodeoxynucleotide penetrates the adventitia and acts to suppress c-myc expression in VSMCs in the media within 2 h. The effect of oligodeoxynucleotide application is not, however, limited to the short term since it leads to marked reduction in neointima formation some 14 d later. As the applied oligodeoxynucleotide is unlikely to persist for very long in vivo, we suggest that the protracted process of neointima formation is critically dependent upon mitogenic events that occur very shortly after injury. Presumably, antisense c-myc oligodeoxynucleotides block entry of VSMCs into the cell cycle and suppress proliferation of those VSMCs already in cycle. Alternatively, it is possible that the antisense c-myc oligodeoxynucleotide interferes with VSMC migration, a process that also contributes to the neointimal lesion (29) . Indeed, antisense c-myc oligodeoxynucleotides have been shown to reduce VSMC migration in vitro, and at somewhat lower doses than those required to reduce proliferation (26) . Our data complement and extend the previous study of Simons et al. ( 13) which demonstrated inhibition of VSMC accumulation in arteries in vivo using antisense oligodeoxynucleotides to block expression of the proto-oncogene c-myb.
Although the reduction in neointimal area after injury demonstrates the potential for the use ofantisense strategies to modulate c-myc expression after angioplasty, further studies are needed to establish whether the suppression of neointima formation is maintained, to determine the minimum effective dose required for neointima suppression and to investigate whether the inhibitory effect is primarily on VSMC proliferation or VSMC migration. Furthermore, in addition to VSMCs, arterial walls contain a variety of cell types that may also be implicated in the neointimal process. Although no effect was observed on medial thickness or wound healing, it will be necessary to examine the relative uptake and effects of antisense oligodeoxynucleotides on each cell type. For example, c-myc expression is likely to be induced in endothelial cells after injury. Antisense c-myc oligodeoxynucleotides may thus suppress endothelial cell division and/or migration which would reduce reendothelialization and could complicate arterial repair. Studies designed to address the above issues are presently underway.
In conclusion, we have demonstrated that antisense oligodeoxynucleotides can be used to suppress c-myc expression in VSMCs both in vitro and in vivo and thereby inhibit VSMC proliferation and formation of neointima after arterial injury. C-myc is thus an essential component of VSMC proliferation and appears to be an excellent target for potential therapies designed to prevent angioplasty restenosis and its associated pathologies.
